Dermata Therapeutics, Inc. (DRMA) Stock Analysis & Investment Frameworks
Dermata Therapeutics, Inc. (DRMA) stock analysis on Invetso. Review Dermata Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Dermata Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Dermata Therapeutics, Inc. Key Financial Metrics
- Market Cap: $817868.00
- Revenue: $N/A
- ROE: -166.67%
- ROIC: -246.61%
- Dividend Yield: N/A
About Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Dermata Therapeutics, Inc. Investment Frameworks
Invetso analyzes Dermata Therapeutics, Inc. (DRMA) across the following frameworks:
- Dermata Therapeutics, Inc. 10Y Growth Potential
- Dermata Therapeutics, Inc. Scenario Analysis
- Dermata Therapeutics, Inc. Risks & Opportunities
- Dermata Therapeutics, Inc. Economic Moat
- Dermata Therapeutics, Inc. Business Model
- Dermata Therapeutics, Inc. Management
- Dermata Therapeutics, Inc. SWOT Analysis
- Dermata Therapeutics, Inc. Porter's 5 Forces
- Dermata Therapeutics, Inc. PESTLE Analysis
- Dermata Therapeutics, Inc. ESG Analysis
